Demand will be for data scientists, developers and cybersecurity specialists, it says
AstraZeneca is currently conducting 50 clinical trials in India
Jubilant Pharma had invested $25 million in Sofie Biosciences in November 2020 and now plans to exit its investment completely
Envafolimab is a first-in-class PD-L1 inhibitor, a type of immunotherapy drug that harnesses the body's immune system to fight cancer
Consumers can secure their E-Luna by pre-booking on the Kinetic Green website for an amount of Rs 500. Kinetic had started a pilot around September in some locations of Maharashtra
Ceat's share price rose by 4.34 per cent, ending the day's trade at Rs 2,875 apiece on the BSE
Lupin boasts 15 manufacturing sites, 7 research centres, and a global team of more than 20,000 professionals
Despite the shift towards a family-centric approach, Mehta assured customers that the Rizta will uphold the quality and reliability synonymous with the Ather brand
The automotive industry has witnessed a trend, with various manufacturers resorting to similar price hikes in the early months of FY24
According to the findings, retrofitting extends the lifespan of vehicles by 8-10 years and offers a faster payback compared to new electric vehicles (EVs)
The company revealed that they are now targeting the Asean markets, starting with the Philippines
Competing in the mid-capacity segment, the Jawa 350 will face off against the Royal Enfield Classic 350 (priced between Rs 1.93 to 2.24 lakh) and Honda H'ness CB 350 (ex-showroom Rs 2.09 - 2.16 lakh)
Experts anticipate indigenous vaccine to help curb cases; health ministry yet to take a decision on rollout
The new facility is spread over 460 acres and is adjacent to Tata Motors' existing passenger vehicle facility in Sanand
According to the Global Trade Research Initiative (GTRI) report on August 2023, the Indian medical devices industry has the potential to expand from $12 billion to $50 billion by 2030
This ambition follows the company's recent approval from Anvisa (Brazilian health regulatory agency), which has facilitated its entry into the Brazilian market
EVRE has set the target to secure a total of Rs 160 crore in equity by the end of 2024 to support its expansion plans
The collaborative effort is aimed at developing and commercialising novel Cell therapy products for critical unmet medical needs in the US, Japan, and the EU
Analysts also feel this move will help improve quality of Indian drugs
This expansion is driven by a combination of factors, including the growing demand for IVF treatment in underserved markets and foreign customers coming in